Adaptimmune’s FDA Approval Marks the First for an Engineered Cell Remedy for Stable Tumors
Cell therapies first reached sufferers as remedies for blood cancers. Adaptimmune Therapeutics’ work on this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory choice that makes the brand new product the primary engineered cell remedy authorized for treating a strong tumor. Recognized in growth as afamitresgene autoleucel, or afami-cel, the








